Manhattan Associates Inc vs Vaxcyte Inc. Common Stock — how do they compare? Manhattan Associates Inc trades at $216.88 (market cap $12.99B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Vaxcyte Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 11 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MANH | PCVX | |
|---|---|---|
Market Cap | $12.99B | $10.51B |
Volume | 546,880 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $223.76 | $73.82 |
52-Week Low | $120.88 | $40.32 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $12.85B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
MANH trades at $222.71, up 2.21% today, with a bullish technical signal and strong profitability metrics including a 96.38% ROE. Recent earnings have consistently beaten expectations, and the company launched new Editions solutions to expand market access. However, high valuation ratios and a legal investigation pose headwinds.
The outlook remains positive with 80% analyst buy ratings and a $219.25 consensus target, but risks include elevated P/E of 63.81 and potential fiduciary breach concerns. Earnings growth and product innovation are key catalysts, yet investors should weigh valuation against legal and competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →